Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
50.13%
Operating Margin
20.37%
Net Margin
9.49%
Efficiency Metrics
Revenue per Expense Ratio
1.26
R&D as % of Revenue
0.15%
Earnings Quality
EBITDA Margin
20.40%
Income Tax Rate
38.75%
EPS
2.3400000000
Balance Sheet Analysis
Current Ratio
2.67
Cash Ratio
1.17
Working Capital
$167.28M
Debt to Equity
2.50
Debt to Assets
66.39%
Equity Ratio
26.52%
Cash Flow Analysis
Operating Cash Flow Ratio
16.50%
Free Cash Flow Ratio
15.09%
CapEx to Revenue
1.41%
Dividends Paid
$4.50M
Stock Buybacks
$995.00K
Total Shareholder Returns
$5.49M
Cash Position Change
10.79%
Key Takeaways (2023 FY)
Revenue declined by 2.3179996771185%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased dividend payments by 7.75%
Detailed Growth Metrics
Core Performance
Revenue
-2.32%
Net Income
230.40%
EPS
260.00%
Operating Income
9.35%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
-4.74%
Operating Cash Flow
120.93%
Free Cash Flow
170.83%
Balance Sheet Health
Assets
-0.48%
Debt
-9.43%
Book Value per Share
36.52%
Inventory
-12.72%
Shareholder Returns
Dividends per Share
7.75%
Shares Outstanding
-1.80%
Long Term Trends
3Y Revenue/Share
10.43%
5Y Revenue/Share
34.18%
3Y Dividend/Share
30.53%
5Y Dividend/Share
113.62%